Descripción de la empresa
Femasys Inc. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it develops therapeutic and diagnostic solutions designed to address unmet women's healthcare needs both in the United States and internationally. The company's portfolio includes offerings such as FemaSeed, an intratubal insemination solution, and FemVue, a companion diagnostic for fallopian tube assessment, which together aim to provide specialized biomedical interventions. Currently, the company has a market capitalization of $23.72M and reports trailing twelve-month revenue of $2.29M, while the number of employees is listed as N/A. These valuation and revenue figures indicate that Femasys is a micro-cap entity with a relatively small financial footprint, suggesting it operates as a niche player in the broader medical device landscape rather than a dominant market leader.
Salud financiera
The financial statements for the trailing twelve months show revenue of $2.29M, a net income of $-18,627,888, and an EBITDA of $-17,246,636, revealing a significant disparity between top-line sales and bottom-line profitability that points to a highly aggressive or inefficient cost structure. Free cash flow stands at $-12,696,886, which indicates that the company is currently burning cash and lacks the immediate financial flexibility to fund operations without external capital injections or equity dilution. The gross margin is reported at 62.0%, suggesting that the core manufacturing or licensing of its products retains high pricing power or low direct production costs relative to sales. However, the operating margin is a negative 568.3% and the profit margin is 0.0%, highlighting that general and administrative expenses are substantially exceeding the gross profit generated from operations. On the balance sheet, the company holds $9.27M in cash against $4.70M in debt, resulting in a debt-to-equity ratio of 80.03, which characterizes a highly leveraged position despite the presence of ample liquid assets. The current ratio is 4.53, indicating strong short-term liquidity as the company possesses more than four times the current assets required to cover its current liabilities. Finally, the return on equity is -455.8% and the return on assets is -66.3%, metrics that reveal that management is currently unable to generate positive returns on the capital invested in the business, reflecting the company's developmental stage and operational losses.
Evaluación de valoración
The valuation metrics present a challenging picture, with a trailing P/E ratio of N/A and a forward P/E of -1.11, implying that the market is not valuing the company based on historical earnings but rather anticipating future profitability that does not yet exist. The price-to-book ratio is 4.09, indicating that the stock is trading at a significant premium of over four times its net asset value, a valuation multiple often seen in speculative micro-cap biotech firms but difficult to justify without clear paths to profitability. Alternative valuation measures such as the price-to-sales ratio of 10.34 and an EV/EBITDA of -1.17 further suggest that investors are pricing in substantial growth expectations rather than current fundamental performance. Regarding price volatility, the 52-week high is $1.29 and the 52-week low is $0.31, meaning the stock is currently trading within a range that reflects significant price discovery and potential downside risk relative to the recent highs. The beta value is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market index but underscores the inherent uncertainty associated with assets lacking historical volatility data.
Growth & Income
Revenue growth year-over-year is 39.9%, demonstrating a robust expansion in sales volume or market penetration, whereas earnings growth is N/A because the company has not yet achieved consistent profitability to support a year-over-year earnings comparison. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available cash flow back into research, development, and operational scaling rather than distributing income to shareholders. This strategic choice to forgo dividends aligns with the typical lifecycle of a biomedical company that prioritizes capital expenditure for product innovation over immediate shareholder returns. Overall, the growth and income profile of Femasys Inc. is characterized by high revenue expansion coupled with significant operational losses and a complete absence of current income generation for investors.